Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-5.91%
$13.38
0% positive prob.
5-Day Prediction
-10.12%
$12.78
0% positive prob.
20-Day Prediction
-8.33%
$13.04
0% positive prob.
SEC 8-K filings with transcript text
Feb 26, 2026 · 100% conf.
1D
-5.91%
$13.38
Act: +8.30%
5D
-10.12%
$12.78
Act: +11.53%
20D
-8.33%
$13.04
8-K
false000143972500014397252026-02-262026-02-26
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 26, 2026 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware
001-39659
20-3986492
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
919 West Dillon Rd Louisville, Colorado (Address of Principal Executive Office)
80027 (Zip Code)
Registrant’s telephone number, including area code: (303) 417-0500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value of $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 26, 2026, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in Item 2.02 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document or filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
No.
Exhibit
99.1
Press Release issued by Biodesix, Inc. dated February 26, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 26, 2026
By:
/s/ Robin Harper Cowie
Name:
Robin Harper Cowie
Title:
Chief Financial Officer
Jan 12, 2026 · 100% conf.
1D
-5.91%
$13.38
Act: +8.30%
5D
-10.12%
$12.78
Act: +11.53%
20D
-8.33%
$13.04
false000143972500014397252026-01-122026-01-12
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 12, 2026 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware
001-39659
20-3986492
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
919 West Dillon Rd Louisville, Colorado (Address of Principal Executive Office)
80027 (Zip Code)
Registrant’s telephone number, including area code: (303) 417-0500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value of $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note Biodesix, Inc. (the Company) is filing this Form 8-K/A to its Current Report on Form 8-K filed on January 12, 2026 solely to recharacterize the press release announcing certain preliminary and unaudited financial results of the Company for the fourth quarter and year ended December 31, 2025 as filed rather than furnished. No other changes have been made. Item 2.02. Results of Operations and Financial Condition. On January 12, 2026, the Company issued a press release announcing certain preliminary and unaudited financial results of the Company for the fourth quarter and year ended December 31, 2025. A copy of the press release is included as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in this Item 2.02 of this Current Report on Form 8-K/A, including Exhibit 99.1 hereto, is being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and shall be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, to the extent specifically incorporated by reference therein. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
No.
Exhibit
99.1
Press Release issued by Biodesix, Inc. dated January 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: January 12, 2026
By:
/s/ Robin Harper Cowie
Name:
Robin Harper Cowie
Title:
Chief Financial Officer
Nov 3, 2025
8-K
0001439725false00014397252025-11-032025-11-03
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2025 Date of Report (Date of earliest event reported) Biodesix, Inc. (Exact Name of Registrant as Specified in Charter)
Delaware
001-39659
20-3986492
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
919 West Dillon Rd Louisville, Colorado (Address of Principal Executive Office)
80027 (Zip Code)
Registrant’s telephone number, including area code: (303) 417-0500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value of $0.001 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 3, 2025, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The information contained in Item 2.02 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document or filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
No.
Exhibit
99.1
Press Release issued by Biodesix, Inc. dated November 3, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 3, 2025
By:
/s/ Robin Harper Cowie
Name:
Robin Harper Cowie
Title:
Chief Financial Officer
This page provides Biodesix Inc. (BDSX) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on BDSX's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.